HK Stock Market Move | ANTIGENE-B (06996) increased by nearly 6%, Xeviox's two supplemental new drug applications approved by the Hong Kong Department of Health.

ANTENGENE-B (06996) rose nearly 6%, and at the time of release, it was up 5.34% to HK$4.34, with a trading volume of HK$9.494 million. On the news front, the Hong Kong Department of Health has approved two supplemental new drug applications for XEVINIO (selinexor), one for the treatment of multiple myeloma (in combination with bortezomib and dexamethasone, for adult patients who have received at least one prior therapy) and the other for the treatment of relapsed or refractory diffuse large B-cell lymphoma (as a monotherapy, for adult patients who have received at least two systemic therapies and are not eligible for stem cell transplant). This approval marks a further expansion for Dachi Medicine in the Hong Kong market, significant for the company's business development. It not only demonstrates the company's continued enhancement in research and development and market promotion capabilities in the field of biopharmaceuticals, but also XEVINIO's approval will meet the treatment needs for related diseases in the Hong Kong market, enhancing the company's competitiveness in the biotechnology industry.